Stock Analiz

enGene Therapeutics Inc. ENGN

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$2.41Market cap $162M
Open the interactive analysis →

enGene Therapeutics Inc. (ENGN) is a healthcare company listed in the US with a market value of about $162M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -36%.

About enGene Therapeutics

enGene Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances). It was profitable in 0 of the last 4 years in our data. Its share count rose by 7703% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-64.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-35.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 4 years

Fiscal year2025202420232022
Revenue————
Net income-$117M-$55M-$100M-$24M
Free cash flow-$101M-$49M-$25M-$18M
EPS (diluted)$2.29$1.46$151.22$44.30
Net margin————
ROIC-61.7%-20.9%-25.0%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 7 analysts is $4.29, 78% above the current price; targets range from $2.00 to $6.00; the consensus rating is “Buy”; expected EPS is $-1.82 for the fiscal year ending October 31, 2026.

Frequently asked questions

Does enGene Therapeutics pay a dividend?

Not currently.

Is enGene Therapeutics a good stock to buy?

We do not give buy or sell advice. enGene Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.